Covid-19 & Obesity: Beyond Bmi

Area of Science:

• Internal Medicine
• Endocrinology
• Public Health

Background:

• The COVID-19 pandemic has caused significant global health issues, with patient characteristics influencing disease severity.
• Obesity, defined as adiposity-based chronic disease, is a recognized risk factor for severe COVID-19 outcomes.
• Further risk stratification in obese patients is crucial for effective mitigation and treatment strategies.

Purpose of the Study:

• To investigate the role of insulin resistance in predicting severe COVID-19 outcomes among individuals with obesity.
• To explore how adiposity-related complications influence COVID-19 severity, independent of body mass index.
• To propose a complication-centric staging approach for assessing COVID-19 risk in obese populations.

Main Methods:

• The study hypothesizes insulin resistance as a key pathophysiological factor.
• It examines the association between obesity, insulin resistance, and COVID-19 severity.
• A complication-centric staging method is proposed, considering conditions like hypertension and type 2 diabetes mellitus.

Main Results:

• Insulin resistance is suspected to be a primary driver of poor COVID-19 outcomes in obese individuals, irrespective of BMI.
• Conditions such as type 2 diabetes mellitus, hypertension, and cardiovascular disease are linked to adverse outcomes due to underlying insulin resistance.
• The proposed staging method aims to pragmatically assess adiposity-related risks in COVID-19 patients.

Conclusions:

• Insulin resistance is a critical factor in understanding severe COVID-19 in patients with obesity.
• A complication-centric approach to staging adiposity-related disease can enhance risk prediction for COVID-19.
• This strategy offers actionable insights for managing and potentially treating obese patients during the pandemic.